Penn spinout Linnaeus Therapeutics gets key FDA designation

A South Jersey biopharmaceutical firm spun out of the University of Pennsylvania got a boost Thursday when the Food and Drug Administration granted orphan drug designation for the company's lead new drug candidate. Linnaeus Therapeutics of Haddonfield received the designation for LNS8801. The experimental treatment is for patients with metastatic uveal melanoma, a rare cancer that occurs within the eye. The FDA's Office of Orphan Drug Products grants orphan status to support drug candidates targeting…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news